CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030
Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies
Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets
CEL-SCI Corporation (NYSE American: CVM) today announced it will participate in a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 in San Diego, California. The ceremony will mark an important milestone in advancing the previously announced strategic agreement between the companies focused on the commercialization and distribution of Multikine®* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia.
